Atlas market file · Equity · United States
Agenus IncAGEN
- Last close
- 7.49
- Change
- -3.73%
- 96-bar range
- 2.85 – 8.84
- As of
- 6 Aug 2026
Agenus Inc is a biological products, (no diagnostic substances) issuer listed as AGEN on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
AGEN
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+29.14% over the window).
Source rail: Yahoo Finance chart API (AGEN). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for AGEN. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
AGEN public profile
Biological products, (no diagnostic substances) issuer. Agenus Inc is connected to current market context, cited company sources and its retained research file.
Agenus Inc trades as AGEN on NASDAQ. Agenus Inc (AGEN) has a latest verified close of 7.49, down 3.73%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files AGEN under USA Stocks for browsing.
What changed for Agenus Inc today
Agenus Inc., a leader in immuno-oncology innovation, has announced an oversubscribed private placement of up to $340 million to advance its registrational ROBBIN trial of neoadjuvant botensilimab and balstilimab in microsatellite-stable colon cancer.
The company's lead clinical program is botensilimab, alone and in combination with balstilimab, which requires successful clinical trials and approvals from regulatory agencies. Agenus has also expanded its global Medical Affairs infrastructure to support increasing physician requests for authorized access to botensilimab plus balstilimab.
According to the company's latest 10-Q filing, revenue from contract with customer, excluding assessed tax, was $33.7 million for the period ending 2026-03-31. Operating income was $15.1 million, and net cash provided by operating activities was -$36.0 million. The company had $35.0 million in cash and cash equivalents as of 2026-03-31.
The recent private placement and the expansion of the Medical Affairs infrastructure are significant developments for Agenus, as the company continues to advance its clinical trials and seek regulatory approvals. The company's pipeline of immunological agents and its focus on immuno-oncology innovation position it for potential growth in the field.
The chart context for Agenus Inc. will be closely watched as the company navigates the challenges of clinical trials and regulatory approvals. The success of the ROBBIN trial and the expansion of the Medical Affairs infrastructure will be key factors in determining the company's future prospects.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
AGEN technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on AGEN
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep AGEN research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
AGEN FAQ
What is Agenus Inc (AGEN)?Agenus Inc (AGEN) has a latest verified close of 7.49, down 3.73%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates,...
Agenus Inc (AGEN) has a latest verified close of 7.49, down 3.73%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for AGEN?Agenus Inc (AGEN) has a latest verified close of 7.49, down 3.73%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the...
Agenus Inc (AGEN) has a latest verified close of 7.49, down 3.73%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files AGEN under USA Stocks for browsing.
How often is the AGEN page updated?The AGEN public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The AGEN public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for AGEN?The AGEN file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:AGEN. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The AGEN file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:AGEN. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on AGEN?Yes. The workstation can open AGEN, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open AGEN, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this AGEN page investment advice?No. The AGEN page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The AGEN page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →